Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
New EMA Advice to Reduce PML Risk With Natalizumab (Tysabri) in MS
Research Advances in Biomarkers for Demyelinating Optic Neuritis.
Pathogenic CD8 T cells in multiple sclerosis and its experimental models.
Comparison of Point Estimates and Average Thicknesses of Retinal Layers Measured Using Manual Optical Coherence Tomography Segmentation for Quantification of Retinal Neurodegeneration in Multiple Sclerosis.
Differential Cerebellar Functional Interactions during an Interference Task across Multiple Sclerosis Phenotypes.
Chronic social stress impairs virus specific adaptive immunity during acute Theiler's virus infection.
Selective ultrastructural vulnerability in the cuprizone-induced experimental demyelination.
Clinical designs of recent robot rehabilitation trials.
Chronic pain following spinal cord injury.
JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
Imaging Phenotypes in Multiple Sclerosis.
Chronic oligodendrogenesis and remyelination after spinal cord injury in mice and rats.
Cell-based therapy approaches: the hope for incurable diseases.
Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.
Managed care aspects of managing multiple sclerosis.
Molecular mimicry in the etiology of autoimmune diseases.
Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Resting State Brain Entropy Alterations in Relapsing Remitting Multiple Sclerosis.
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.
Tumefactive demyelinating lesions: A Clinicopathological correlative study.
Exercise for Managing the Symptoms of Multiple Sclerosis.
Astrocytic vesicle mobility in health and disease.
Patient autonomy in multiple sclerosis - Possible goals and assessment strategies.
Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: A case control study.
Pages
« first
‹ previous
…
274
275
276
277
278
279
280
281
282
…
next ›
last »